Beaufort Securities reaffirmed their buy rating on shares of Hutchison China MediTech (LON:HCM) in a research note issued to investors on Wednesday.

Hutchison China MediTech (LON HCM) traded up GBX 129.75 ($1.79) during trading on Wednesday, reaching GBX 4,674.75 ($64.59). 10,951 shares of the company’s stock traded hands, compared to its average volume of 7,732. The company has a market cap of $2,690.00 and a price-to-earnings ratio of 31,165.00. Hutchison China MediTech has a 52-week low of GBX 2,069.61 ($28.59) and a 52-week high of GBX 5,932 ($81.96).

WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at

About Hutchison China MediTech

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Ratings for Hutchison China MediTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech and related companies with's FREE daily email newsletter.